AU2001233132A1 - Hybrid adeno-retroviral vector for the transfection of cells - Google Patents

Hybrid adeno-retroviral vector for the transfection of cells

Info

Publication number
AU2001233132A1
AU2001233132A1 AU2001233132A AU3313201A AU2001233132A1 AU 2001233132 A1 AU2001233132 A1 AU 2001233132A1 AU 2001233132 A AU2001233132 A AU 2001233132A AU 3313201 A AU3313201 A AU 3313201A AU 2001233132 A1 AU2001233132 A1 AU 2001233132A1
Authority
AU
Australia
Prior art keywords
transfection
cells
retroviral vector
hybrid adeno
adeno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233132A
Inventor
Bruce J. Baum
Brian O'connell
Changyu Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001233132A1 publication Critical patent/AU2001233132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
AU2001233132A 2000-01-31 2001-01-30 Hybrid adeno-retroviral vector for the transfection of cells Abandoned AU2001233132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17932700P 2000-01-31 2000-01-31
US60179327 2000-01-31
PCT/US2001/003026 WO2001055362A2 (en) 2000-01-31 2001-01-30 Hybrid adeno-retroviral vector for the transfection of cells

Publications (1)

Publication Number Publication Date
AU2001233132A1 true AU2001233132A1 (en) 2001-08-07

Family

ID=22656101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233132A Abandoned AU2001233132A1 (en) 2000-01-31 2001-01-30 Hybrid adeno-retroviral vector for the transfection of cells

Country Status (3)

Country Link
US (3) US7052904B2 (en)
AU (1) AU2001233132A1 (en)
WO (1) WO2001055362A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061104A2 (en) * 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
PL2484375T3 (en) 2006-09-26 2018-09-28 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TWI549688B (en) 2009-06-05 2016-09-21 美國疾病傳染研究機構 Synthetic glucopyranosyl lipid adjuvants
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EA027236B1 (en) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20140140962A1 (en) * 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
HUE044841T2 (en) 2012-02-07 2019-11-28 Infectious Disease Res Inst Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
JP6426706B2 (en) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP3458475B1 (en) 2016-05-16 2022-07-27 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
KR102472026B1 (en) 2016-06-01 2022-11-30 액세스 투 어드밴스드 헬스 인스티튜트 Nanoalum Particles Containing Sizing Agent
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN111315406A (en) 2017-09-08 2020-06-19 传染病研究所 Liposome formulations comprising saponins and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
FR2716459B1 (en) 1994-02-22 1996-05-10 Univ Paris Curie Host-vector system usable in gene therapy.
FR2723697B1 (en) 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa METHOD OF TREATING RESTENOSIS WITH GENE THERAPY
EP0787200B1 (en) 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
EP0927263A1 (en) * 1996-01-05 1999-07-07 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
EP0956052B1 (en) * 1996-11-19 2005-04-13 University Of Alabama, Birmingham Research Foundation Chimeric retrovirus/adenovirus system
JP2001526900A (en) 1997-12-23 2001-12-25 イントロヘーネ ベスローテン フェンノートシャップ Adeno-associated virus and chimeric adenovirus recombinant virus useful for integrating foreign gene information into chromosomal DNA of target cells
CA2327444A1 (en) * 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
GB9906615D0 (en) 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
US20020150876A1 (en) * 2000-03-30 2002-10-17 Pippig Susanne Dagmar Selectable marker genes
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector

Also Published As

Publication number Publication date
US7618623B2 (en) 2009-11-17
US20040115788A1 (en) 2004-06-17
WO2001055362A3 (en) 2002-01-10
US20060035371A1 (en) 2006-02-16
US7052904B2 (en) 2006-05-30
US20090258935A1 (en) 2009-10-15
WO2001055362A2 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
AU2001233132A1 (en) Hybrid adeno-retroviral vector for the transfection of cells
AU3706700A (en) Positively charged membrane
AU2002222112A1 (en) Hybrid antibodies
AU2001240126A1 (en) Lithium cell
AU2002351249A1 (en) Battery charging system
EP1130098A3 (en) Mammalian osteoregulins
AU2002241571A1 (en) Multi-cell battery
AU3376400A (en) Negatively charged membrane
AU5003600A (en) Charged membrane
AU2926000A (en) Packaging cells for retroviral vectors
AU5854100A (en) Lithium cell
AU2003220161A1 (en) Vector for transfection of eukaryotic cells
AU2002237701A1 (en) Rapid battery charger
AU2001232054A1 (en) Vector
AUPQ529000A0 (en) Toner characterization cell
AU2001287064A1 (en) Battery
AU2001267724A1 (en) Electrochemical cell
AU2001257429A1 (en) Battery
AU2001257430A1 (en) Battery
AU5250100A (en) Vector for expressing two foreign genes
AU2001269081A1 (en) Electrochemical cells
AU4494300A (en) Powertrain for power generator
AU7964400A (en) Lithium secondary cell
AU2002213328A1 (en) Battery
AU1595401A (en) Lithium primary batteries